5 Best Immunotherapy Stocks To Buy Now

2. Novavax, Inc. (NASDAQ:NVAX)

Number of Hedge Fund Holders: 25     

Novavax, Inc. (NASDAQ:NVAX) is a biotechnology company that focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. On August 10, B Riley analyst Mayank Mamtani maintained a Buy rating on Novavax, Inc. (NASDAQ:NVAX) stock and lowered the price target to $126 from $171, underlining that COVID vaccine product sales were meaningfully below Street expectations and the fiscal 2022 outlook was worse than feared for the firm. 

Among the hedge funds being tracked by Insider Monkey, Chicago-based investment firm Graham Capital Management is a leading shareholder in Novavax, Inc. (NASDAQ:NVAX), with 85 million shares worth more than $85 million.